Literature DB >> 29388012

Large sporadic thyroid medullary carcinomas: predictive factors for lymph node involvement.

Sébastien Aubert1,2,3, Amandine Berdelou4, Viviane Gnemmi5,6,7, Hélène Behal8, Robert Caiazzo6,9, Michèle D'herbomez10, Pascal Pigny6,7,10, Jean Louis Wemeau6,11, Bruno Carnaille6,9, Florence Renaud5,6,7, Brigitte Bouchindhomme5, Emmanuelle Leteurtre5,6,7, Michael Perrais6,7, François Pattou6,9, Christine Do Cao11.   

Abstract

Lymph node involvement (LNI) is one of the most important prognostic factors for poor survival in medullary thyroid carcinoma (MTC). At diagnosis, LNI is found in over 50% of sporadic MTCs, and especially in large tumours. Cervical lymph node dissection is therefore mandatory during MTC surgery. However, some large tumours (responsible for high preoperative basal calcitonin levels) are found to lack LNI, and can be cured definitely. Preoperative detection of these particular tumours might spare patients from undergoing extensive cervical dissection. The objective of the present retrospective study of a series of large sporadic MTCs was to identify clinical, biological and pathological factors that were predictive of LNI. Consecutive cases of large, sporadic MTCs (measuring at least 1 cm in diameter) were retrieved and reviewed. The levels of several mature microRNAs (miRs) in paraffin-embedded samples were assessed using qPCR. Of the 54 MTCs, 26 had LNI and 28 were pN0. Relative to pN0 patients, patients with LNI had a significant higher preoperative basal calcitonin level (p = 0.0074) and a greater prevalence of infiltrative margins (p < 0.0001), lymphovascular invasion (p = 0.0004), extrathyroidal extension (p < 0.0001), a higher pT stage (p = 0.0003) and more abundant desmoplastic stroma (p = 0.0006). Tumour expression levels of miR-21 (p = 0.0008) and miR-183 (p = 0.0096) were higher in the LNI group. The abundance of desmoplastic stroma (p = 0.007) and the miR-21 expression level (p = 0.0026) were independent prognostic factors for LNI. The abundance of desmoplastic stroma and high levels of miR-21 expression were strong indicators of LNI, and may thus help the surgeon to choose the extent of cervical lymph node dissection for large, sporadic MTCs with no preoperatively obvious LNI.

Entities:  

Keywords:  Carcinoma; Desmoplasia; Medullary; MicroRNA; Node; Thyroid

Mesh:

Year:  2018        PMID: 29388012     DOI: 10.1007/s00428-018-2303-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  28 in total

Review 1.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

2.  Clinical relevance of desmoplasia in medullary thyroid carcinoma.

Authors:  A Machens; H Dralle
Journal:  Histopathology       Date:  2008-10       Impact factor: 5.087

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 4.  Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas.

Authors:  Bartosz Wojtas; Carolina Ferraz; Tomasz Stokowy; Steffen Hauptmann; Dariusz Lange; Henning Dralle; Thomas Musholt; Barbara Jarzab; Ralf Paschke; Markus Eszlinger
Journal:  Mol Cell Endocrinol       Date:  2014-03-12       Impact factor: 4.102

5.  The PDCD4/miR-21 pathway in medullary thyroid carcinoma.

Authors:  Gianmaria Pennelli; Francesca Galuppini; Susi Barollo; Elisabetta Cavedon; Loris Bertazza; Matteo Fassan; Vincenza Guzzardo; Maria Rosa Pelizzo; Massimo Rugge; Caterina Mian
Journal:  Hum Pathol       Date:  2014-10-02       Impact factor: 3.466

6.  MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets.

Authors:  Deepak Abraham; Nicole Jackson; Justin S Gundara; JingTing Zhao; Anthony J Gill; Leigh Delbridge; Bruce G Robinson; Stan B Sidhu
Journal:  Clin Cancer Res       Date:  2011-05-27       Impact factor: 12.531

7.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer.

Authors:  Andreas Machens; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2010-03-25       Impact factor: 5.958

8.  Inherited medullary microcarcinoma of the thyroid: a study of 11 cases.

Authors:  J E Krueger; A Maitra; J Albores-Saavedra
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

9.  The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development.

Authors:  Zhengping Zhang; Yinhe Zha; Wei Hu; Zhen Huang; Zhongfei Gao; Yuhui Zang; Jiangning Chen; Lei Dong; Junfeng Zhang
Journal:  J Biol Chem       Date:  2013-11-06       Impact factor: 5.157

10.  Prediction of lateral lymph node metastases in medullary thyroid cancer.

Authors:  A Machens; S Hauptmann; H Dralle
Journal:  Br J Surg       Date:  2008-05       Impact factor: 6.939

View more
  6 in total

Review 1.  Is Encapsulated Medullary Thyroid Carcinoma Associated With a Better Prognosis? A Case Series and a Review of the Literature.

Authors:  Andrea Contarino; Alessia Dolci; Marco Maggioni; Francesca Maria Porta; Gianluca Lopez; Uberta Verga; Francesca Marta Elli; Elisabetta Francesca Iofrida; Gianmaria Cantoni; Giovanna Mantovani; Maura Arosio
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-27       Impact factor: 6.055

2.  Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma.

Authors:  M M Moura; R A Cabrera; S Esteves; B M Cavaco; P Soares; V Leite
Journal:  J Endocrinol Invest       Date:  2021-02-11       Impact factor: 4.256

Review 3.  MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives.

Authors:  Francesca Galuppini; Simona Censi; Margherita Moro; Stefano Carraro; Marta Sbaraglia; Maurizio Iacobone; Matteo Fassan; Caterina Mian; Gianmaria Pennelli
Journal:  Cells       Date:  2021-04-20       Impact factor: 6.600

4.  Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines.

Authors:  Daqi Zhang; Carla Colombo; Hui Sun; Hoon Yub Kim; Antonella Pino; Simone De Leo; Giacomo Gazzano; Luca Persani; Gianlorenzo Dionigi; Laura Fugazzola
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-11       Impact factor: 6.055

5.  The Prognostic Value of MicroRNAs in Thyroid Cancers-A Systematic Review and Meta-Analysis.

Authors:  Cristina Alina Silaghi; Vera Lozovanu; Horatiu Silaghi; Raluca Diana Georgescu; Cristina Pop; Anca Dobrean; Carmen Emanuela Georgescu
Journal:  Cancers (Basel)       Date:  2020-09-12       Impact factor: 6.639

6.  DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas.

Authors:  M Ingenwerth; T Brandenburg; D Führer-Sakel; M Goetz; F Weber; H Dralle; H-U Schildhaus; K W Schmid; S Theurer
Journal:  Endocr Connect       Date:  2021-03       Impact factor: 3.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.